The Acute Ischemic Stroke Drugs Market in Taiwan is undergoing steady development, supported by a robust healthcare infrastructure and an aging population highly susceptible to cerebrovascular diseases. Stroke remains one of the leading causes of death and disability in Taiwan, and the demand for effective pharmacological interventions has grown accordingly. One of the primary drivers of this market is the increasing awareness about early diagnosis and treatment of stroke, particularly the critical window within which thrombolytic agents like tissue plasminogen activators (tPAs) must be administered. Taiwan’s government and medical institutions have been active in promoting stroke awareness campaigns and expanding emergency medical response systems, which in turn facilitates the timely administration of acute stroke drugs.
TABLE - Taiwan Acute Ischemic Stroke Drugs Market Size & Forecast By Drug Class 2021-2033
Drug Class | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Thrombolytics | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Anticoagulant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Antiplatelet | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Neuroprotective Agent | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis